Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nisoldipine
Drug ID BADD_D01570
Description Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Indications and Usage For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Marketing Status approved
ATC Code C08CA07
DrugBank ID DB00401
KEGG ID D00618
MeSH ID D015737
PubChem ID 4499
TTD Drug ID D0S5CU
NDC Product Code 0378-2097; 66993-473; 13672-042; 0378-2222; 0378-2099; 70515-503; 49706-1607; 13672-041; 13672-043; 0378-2223; 66993-472; 0378-2096; 0378-2098; 70515-501; 0378-2224; 66993-475; 70515-500
UNII 4I8HAB65SZ
Synonyms Nisoldipine | Bay K 5552
Chemical Information
Molecular Formula C20H24N2O6
CAS Registry Number 63675-72-9
SMILES CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Headache17.14.01.001--
Hepatomegaly09.01.05.001--Not Available
Herpes simplex23.11.05.004; 11.05.02.001--Not Available
Herpes zoster23.11.05.005; 17.09.03.026; 11.05.02.003--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypokalaemia14.05.03.002--
Hypotension24.06.03.002--
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Keratitis06.04.02.002--
Lacrimation increased06.08.02.004--
Laryngitis22.07.03.001; 11.01.13.001--
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Melaena24.07.02.013; 07.12.02.004--Not Available
Mental disability26.01.01.001--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle spasms15.05.03.004--
Muscular weakness15.05.06.001; 17.05.03.005--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene